Elpis Biopharmaceuticals

Executive Summary

Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation bispecific armored CAR-T therapies for solid tumors. The company's proprietary platforms address key challenges in the field, including tumor heterogeneity and the immunosuppressive tumor microenvironment, through multi-mechanism armor technology and a cytokine cocktail-based cell manufacturing process. While still in pre-clinical development, Elpis's innovative approach holds promise for improving outcomes in solid tumor indications. The company is privately held and based in Cambridge, MA, with a focus on first- and best-in-class candidates. Key risks include early-stage development hurdles and competition from other CAR-T players.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Candidate70% success
• Q4 2026Preclinical Proof-of-Concept Data80% success
• H2 2027Potential Partnership or Licensing Deal50% success